Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
This modification eliminates the oxidation-prone thioether side chain present in native -MSH, substantially improving the peptides chemical stability without compromising receptor engagement
People who want the entire supply upfront
The treatment is known to deliver impressive before-and-after transformations, with one clinical trial showing that 36% of participants lost around 20% of their body weight over 104 weeks
Let it sit for a few minutes
GLP-1 receptor agonists mimic gut hormones to curb appetite and slow digestion, a mechanism driving the success of therapies from Novo Nordisk (Ozempic for diabetes and Wegovy for Lillys oral GLP-1 drug orforglipron achieves 12.4% weight loss in phase 3 trial but trails injectable rivals tirzepatide and retatrutide Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes
